Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
Status:
RECRUITING
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).
Phase:
PHASE2
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University